네트워크분석을 통한 바이오 및 합성 의약품 안전평가기술 국가연구개발 동향

National Research and Development Trends related to Safety Evaluation Technology of Biologics and Chemical Synthetic Drug: A Network Analysis

It is important to compare the differences in safety evaluation trends of chemical drugs, which have been mainstream in the existing pharmaceutical field, and emerging biologic drugs. Therefore, this study conducted network analyses on government-granted Research and Development (R&D) projects across biopharmaceuticals and chemicalsynthetic drugs. Information on research projects conducted between 2002 and 2017 was extracted from the National Science and Technology Information Service. The projects were categorized into four groups (2002-2006, 2007-2011, 2012-2016, and 2017). We visualized networks using NetMiner ver.4 (Cyram Inc). The research on biologics increased from 593 projects in 2002-2006 to 2,001 projects in 2012-2016; those on synthetic drugs increased from 3,376 projects to 4,741. The network for biologics becomes complicated by not only focusing on evaluation technology but connecting with safety and use while the network for synthetic drugs gets simple with centered knots of safety and use. For both, researches related to evaluation technology have been increasing. To establish appropriate regulatory policies for biologics, a blueprint of R&D covering evaluation technology, safety, and use needs to be planned.